Onconetix Inc (ONCO)

Jun 05, 2025

Onconetix Stockholders Approve Reverse Stock Split Proposal - TipRanks

Jun 05, 2025

Jun 02, 2025

Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com

Jun 02, 2025

Jun 02, 2025

Onconetix, Inc. SEC 10-K Report - TradingView

Jun 02, 2025

May 23, 2025

Onconetix receives additional delisting notice from Nasdaq - Yahoo Finance

May 23, 2025

May 22, 2025

Onconetix faces potential Nasdaq delisting over filing delays By Investing.com - Investing.com Nigeria

May 22, 2025

May 22, 2025

Onconetix receives additional notice from Nasdaq - MSN

May 22, 2025

May 22, 2025

Onconetix Faces Nasdaq Delisting Notice Amid Compliance Issues - TipRanks

May 22, 2025

May 22, 2025

Onconetix faces potential Nasdaq delisting over filing delays - Investing.com Australia

May 22, 2025

May 22, 2025

Onconetix, Inc. Receives Nasdaq Delisting Letter for Failure to File Quarterly Report and Maintain Minimum Bid Price Requirements - Nasdaq

May 22, 2025

May 22, 2025

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewswire

May 22, 2025

May 22, 2025

Onconetix Faces Triple Threat: Nasdaq Delisting Risk Over Missing Filings and 10-Cent Stock Price - Stock Titan

May 22, 2025

May 09, 2025

Noram Receives Results for CVZ-66: High of 1540 ppm Intersection of 220ft (67.1 m) Averaging 1124 ppm of Lithium - The Globe and Mail

May 09, 2025

May 02, 2025

ONCOOnconetix Latest Stock News & Market Updates - Stock Titan

May 02, 2025

May 02, 2025

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - Barchart.com

May 02, 2025

Apr 30, 2025

Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan

Apr 30, 2025

Apr 29, 2025

Onconetix Inc [ONCO] Is Currently 14.45 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

Apr 29, 2025

Apr 29, 2025

Onconetix Inc (ONCO) expanding its growth trajectory ahead - Sete News

Apr 29, 2025

Apr 28, 2025

ONCO Stock on the Rise: A Promising Investment - investchronicle.com

Apr 28, 2025

Apr 28, 2025

This morning’s top pick is Onconetix Inc (NASDAQ:ONCO) - uspostnews.com

Apr 28, 2025

Apr 22, 2025

Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News

Apr 22, 2025

Apr 22, 2025

ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 22, 2025

Apr 22, 2025

Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN

Apr 22, 2025

Apr 21, 2025

Form 8-KCurrent report - ADVFN

Apr 21, 2025

Apr 21, 2025

Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals

Apr 21, 2025

Apr 19, 2025

Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India

Apr 19, 2025

Apr 18, 2025

Onconetix faces Nasdaq delisting over low share price - Investing.com

Apr 18, 2025

Apr 14, 2025

ONCO’s current quarter earnings: What analysts forecast? - uspostnews.com

Apr 14, 2025

Apr 08, 2025

ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Cincinnati's Onconetix pursuing merger deal with drug development firm - The Business Journals

Apr 08, 2025

Apr 08, 2025

Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Onconetix eyes Ocuvex in potential merger to expand portfolio By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq

Apr 08, 2025

Apr 08, 2025

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - The Manila Times

Apr 08, 2025

Apr 08, 2025

Max Alderman, Partner at FE International, Recognized as a NACVA 2024 30 Under Thirty Honoree - The Manila Times

Apr 08, 2025

Apr 08, 2025

Onconetix eyes Ocuvex in potential merger to expand portfolio - Investing.com

Apr 08, 2025

Apr 08, 2025

Target Corp (TGT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com

Apr 08, 2025

Apr 08, 2025

Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan

Apr 08, 2025

Apr 05, 2025

Another top executive departs Cincinnati public firm - WKRC

Apr 05, 2025

Apr 04, 2025

Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader - The Business Journals

Apr 04, 2025

Apr 03, 2025

Onconetix Names Interim CFO Karina Fedasz as Interim CEO - MarketWatch

Apr 03, 2025

Apr 03, 2025

Onconetix Appoints Karina Fedasz as Interim CEO - TipRanks

Apr 03, 2025

Apr 01, 2025

Onconetix Delays Yearly Report Filing - TipRanks

Apr 01, 2025

Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025

Mar 25, 2025

Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire

Mar 25, 2025

Mar 24, 2025

Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India

Mar 24, 2025

Mar 24, 2025

Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq

Mar 24, 2025

Mar 24, 2025

Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq

Mar 24, 2025